Moreover, trimester‐specific data on the variation of CD5L during pregnancy are not yet at hand, it is unknown whether it qualifies as biomarker in women under T4 treatment, and in particular whether it provides diagnostic information in pregnant women with thyroid or hepatic disease. The gene discussed is CD5L; the disease is liver disorder.